全球肽类癌症疫苗市场规模（按类型、技术、应用、区域范围和预测）

肽类癌症疫苗的市场规模及预测

2024 年胜肽癌症疫苗市场规模价值 8.9085 亿美元，预计到 2032 年将达到 33.3704 亿美元，预测期内（2026-2032 年）的复合年增长率为 19.80%。

全球肽类癌症疫苗市场正经历强劲增长，这得益于癌症患者数量的增加、技术进步、新型癌症疗法的研发、政府支持的增加、老龄人口的扩大以及肽类癌症疫苗的长期影响和选择性。近三分之一的癌症死亡病例归因于吸烟、高体重指数、饮酒、水果和蔬菜摄取量低以及缺乏体能活动。因此，预防和治疗癌症所需的癌症疫苗需求很高，这推动了胜肽类癌症疫苗市场的领先。全球肽类癌症疫苗市场报告对市场进行了全面评估，全面分析了关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及在市场中发挥关键作用的因素。

推动全球胜肽类癌症疫苗市场的因素

胜肽癌症疫苗市场的市场驱动因素可能受到多种因素的影响，其中包括：

癌症发生率不断上升：癌症发生率不断上升：全球癌症发生率持续上升，对疫苗接种等有效癌症治疗的需求也随之增加。

免疫疗法的发展：包括癌症疫苗在内的免疫疗法因其个人化标标靶治疗的前景，近年来引起了广泛的兴趣。

人们对精准医疗的兴趣日益浓厚：胜肽类癌症疫苗是精准医疗运动的一个组成部分，精准医疗旨在根据每位患者的基因组成和癌症的具体特征为其定制治疗方案。

技术发展：胜肽合成、疫苗传递方法和生物资讯学的进步都在提高胜肽癌症疫苗的功效和发展，增强其作为治疗选择的潜力。

资金筹措：公共和私营部门对癌症疫苗研发的资金增加正在促进基于胜肽的疫苗的製造和商业化。

有利的法规环境：监管机构对癌症疫苗前景的认可度不断提高，这些尖端治疗方法的许可程序也得到简化，并有望扩大市场。

医疗支出不断上涨：随着全球医疗成本不断上涨，人们和医疗专业人员更愿意考虑胜肽癌症疫苗等尖端治疗方法。

伙伴关係和协作：研究中心、生物技术公司和製药公司正在共同努力促进创新并加速胜肽癌症疫苗的研发和广泛分发。

提高意识和接受度：随着患者和医疗保健提供者对癌症疫苗的了解不断增加以及采取更积极的医疗管理措施，胜肽癌症疫苗正变得越来越广泛地被接受。

联合治疗潜力：胜肽类癌症疫苗与放射线治疗、化疗、查核点抑制剂等其他癌症治疗方法合併使用时，疗效较佳，具有巨大的市场潜力。

限制全球胜肽类癌症疫苗市场的因素

多种因素可能会对胜肽癌症疫苗市场造成限制和挑战，其中一些因素如下：

开发成本高：胜肽类癌症疫苗的研发成本很高，包括临床试验、生产製造、监管核准程序等成本。如此高的价格可能会阻碍投资并阻碍疫苗技术的进步。

疫苗设计的复杂性：成功设计胜肽类癌症疫苗需要对肿瘤抗原和免疫反应有透彻的了解。选择正确抗原的难度可能会显着延迟个人化疫苗的研发进程。

监管障碍：新疫苗的监管核准流程复杂且耗时。肽类癌症疫苗必须经过广泛的测试，以证明其安全性、有效性和生产一致性，这可能会推迟其上市。

疗效有限：胜肽类癌症疫苗作为一种客製化治疗方法很有前景，但患者对癌细胞产生强烈而持久的免疫反应的能力各不相同，并且在许多癌症类型和患者群体中仍然难以实现一致的疗效。

与其他治疗方法的竞争：免疫查核点抑制剂、放射线治疗、化疗、标靶治疗等是一些胜肽类癌症疫苗必须与之竞争的癌症治疗方法。由于这些治疗方法已确立的市场地位和已证明的优势，胜肽类疫苗可能难以广泛应用。

可近性和可负担性：高昂的医疗费用、医疗基础设施的缺乏以及报销问题可能会限制当地获得胜肽疫苗。疫苗业务要发展壮大，至关重要的是确保各地患者都能获得疫苗，并且负担得起。

安全性问题：胜肽癌症疫苗的采用可能会受到安全问题的影响，包括潜在的副作用和自体免疫反应，需要透过严格的疫苗设计和临床试验来解决这些问题，以获得医生和患者的信任。

智慧财产权问题：胜肽类癌症疫苗的相关权利可能引发智慧财产权纠纷，阻碍该领域的合作与发展。促进相关人员之间的合作并消除智慧财产权障碍对于市场扩张至关重要。

目录

第一章 胜肽类癌症疫苗的全球市场介绍

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章全球胜肽癌症疫苗市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

第五章全球胜肽类癌症疫苗市场（依技术）

• 概述
• 重组癌症疫苗
• 全细胞癌症疫苗
• 病毒载体和DNA癌症疫苗
• 其他技术（树突细胞、抗原等）

第六章全球胜肽癌症疫苗市场（按应用）

• 概述
• 乳癌
• 肺癌
• 黑色素瘤
• 摄护腺癌
• 其他的

第七章全球胜肽癌症疫苗市场（按类型）

• 概述
• 个性化胜肽疫苗
• 肽脉衝树突状细胞癌症疫苗
• 胜肽鸡尾酒类型
• 多效价肽疫苗
• 其他的

第八章全球胜肽类癌症疫苗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 其他的
  • 拉丁美洲
  • 中东和非洲

第九章全球胜肽类癌症疫苗市场的竞争格局

• 概述
• 各公司市场排名
• 重点发展策略

第十章 公司简介

• OSE Immunotherapeutics
• GlaxoSmithKline PLC
• Moderna Inc.
• Merck and Co Inc.
• F Hoffmann-La Roche AG
• BrightPath BIoTherapeutics
• Boston Biomedical
• VAXON BIoTech
• Generex BIoTechnology
• ISA Pharmaceuticals

第十一章 重大进展

• 产品发布/开发
• 合併与收购
• 业务扩展
• 伙伴关係与合作

第十二章 附录

• 相关调查

Peptide Cancer Vaccine Market Size And Forecast

Peptide Cancer Vaccine Market size was valued at USD 890.85 Million in 2024 and is projected to reach USD 3337.04 Million by 2032, growing at a CAGR of 19.80% during the forecast period 2026-2032.

The Global Peptide Cancer Vaccine Market has witnessed strong growth owing to a rise in the number of cancer patients, technological advancements, new cancer drug advances, increasing government aid, the expanding older population, and the peptide cancer vaccine's long-term impact and selectivity. Almost one-third of cancer deaths are caused by tobacco use, a high BMI, alcohol use, a low fruit and vegetable intake, and a lack of physical exercise. As a result, there is a high need for cancer vaccines to prevent and cure cancer, moving the market for peptide cancer vaccines ahead. The Global Peptide Cancer Vaccine Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Peptide Cancer Vaccine Market Drivers

The market drivers for the Peptide Cancer Vaccine Market can be influenced by various factors. These may include:

Growing Cancer Incidence: As cancer rates continue to rise worldwide, there is an increasing need for cancer treatments that work, such as vaccinations.

Developments in Immunotherapy: With its promise to provide individualised and targeted treatment choices, immunotherapy, including cancer vaccines, has received a lot of interest in recent years.

Increasing Interest in Precision Medicine: Peptide cancer vaccines are a component of the larger movement in precision medicine, which attempts to customise care for each patient according to their genetic composition and unique cancer traits.

Technological developments: Peptide synthesis, vaccine delivery methods, and bioinformatics have all advanced, improving the efficacy and development of peptide cancer vaccines and raising their prospects as a therapeutic option.

funding in Research and Development: The creation and commercialization of peptide-based vaccinations have been expedited by increased public and private sector funding in the study and development of cancer vaccines.

Positive Regulatory Environment: As a result of regulatory bodies' growing recognition of the promise of cancer vaccines and their streamlining of the licencing procedures for these cutting-edge therapies, the market is poised to expand.

Growing Healthcare Expenditure: As healthcare costs rise globally, people and healthcare professionals are becoming more open to investigating cutting-edge therapy options such peptide cancer vaccines.

Partnerships and Collaborations: Research centres, biotechnology companies, and pharmaceutical corporations are working together to promote innovation and hasten the creation and broader distribution of peptide cancer vaccines.

Growing Awareness and Acceptance: Peptide cancer vaccines are becoming more widely accepted as a result of increased patient and healthcare professional knowledge about cancer vaccines as well as a move towards proactive healthcare management.

Possibility for Combination Therapies: Peptide cancer vaccines can be more effective and have a larger market potential when used in conjunction with other cancer treatments such radiation therapy, chemotherapy, and checkpoint inhibitors.

Global Peptide Cancer Vaccine Market Restraints

Several factors can act as restraints or challenges for the Peptide Cancer Vaccine Market. These may include:

High Development Costs: Peptide cancer vaccines have high research and development costs, including expenses for clinical trials, production, and regulatory approval procedures. These expensive prices may discourage investment and impede the advancement of vaccine technology.

Complexity of Vaccine Design: A thorough understanding of tumour antigens and immune responses is necessary to design successful peptide cancer vaccines. The process of developing vaccines that are customised for each patient can be slowed significantly by the difficulties involved in selecting appropriate antigens.

Regulatory Obstacles: The approval procedures for new vaccinations under regulation can be difficult and time-consuming. To prove safety, efficacy, and manufacturing consistency, peptide cancer vaccines must go through extensive testing, which may cause a delay in their release onto the market.

Limited Efficacy: Peptide cancer vaccines show promise as a customised therapeutic approach, but patient-to-patient variability exists in their ability to mount a strong and long-lasting immune response against cancer cells. It is still difficult to achieve consistent efficacy across many cancer types and patient demographics.

Competition from Other Therapies: Immune checkpoint inhibitors, radiation therapy, chemotherapy, and targeted therapies are some of the cancer treatment methods that peptide cancer vaccines must contend with. It may be difficult for peptide vaccines to become widely used due to the established market positions and shown benefits of these treatments.

Accessibility and affordability: High expenses, a dearth of healthcare infrastructure, and problems with reimbursement may restrict a region's capacity to obtain peptide cancer vaccines. For the vaccine business to expand, it is imperative that vaccinations remain accessible and affordable for patients everywhere.

Safety Concerns: Adoption of peptide cancer vaccines may be impacted by safety concerns, which include possible adverse effects and autoimmune reactions. Gaining the trust of doctors and patients requires addressing safety concerns through meticulous vaccine design and clinical testing.

Intellectual Property Problems: Rights to peptide cancer vaccines may give rise to intellectual property conflicts that impede cooperation and progress in the field. Promoting cooperation among stakeholders and removing obstacles related to intellectual property are crucial for expanding the market.

Global Peptide Cancer Vaccine Market: Segmentation Analysis

The Global Peptide Cancer Vaccine Market is segmented on the basis of Type, Technology, Application, And Geography.

Peptide Cancer Vaccine Market, By Type

• Personalized Peptide Vaccine
• Peptide-Pulsed Dendritic Cancer Vaccine
• Peptide Cocktail Type
• Multivalent Peptide Vaccine
• Others

Based on Type, The market is segmented into Personalized Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine, Peptide Cocktail Type, Multivalent Peptide Vaccine, and Others. The Peptide-Pulsed Dendritic Cancer Vaccine segment holds the largest market share during the forecast period. With the application of the Peptide-Pulsed Dendritic Cancer Vaccine, most of the problems associated with cancer immunotherapy are expected to be resolved.

Peptide Cancer Vaccine Market, By Technology

• Recombinant Cancer Vaccines
• Whole-cell Cancer Vaccines
• Viral Vector and DNA Cancer Vaccines
• Other Technologies (Dendritic Cells, Antigen, etc.)

Based on Technology, The market is segmented into Recombinant Cancer Vaccines, Whole-cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines, and Other Technologies (Dendritic Cells, Antigen, etc.). The Recombinant Cancer Vaccines sector now leads the worldwide market and is projected to do so for the foreseeable future. This is due to the enormous number of cancer vaccinations that have been licensed utilizing recombinant technology. This comprises inserting DNA encoding an antigen into mammalian cells that activates an immune reaction, expressing the antigen in these cells, and then extracting it from them.

Peptide Cancer Vaccine Market, By Application

• Breast Cancer
• Lung Cancer
• Melanoma
• Prostate Cancer
• Others

Based on Application, The market is segmented into Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Others. The Prostate Cancer segment is estimated to witness the highest CAGR during the forecast period. The factors that can be attributed to the rise in demand for Provenge (prostate cancer vaccine) along with the increase in the number of prostate cancer vaccines in the pipeline are fueling the demand for this segment.

Peptide Cancer Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Regional Analysis, The Global Peptide Cancer Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The Peptide Cancer Vaccine Market is expected to have the most growth in North America. The presence of a significant number of biotech and pharmaceutical participants in this area is supporting the demand for the Peptide Cancer Vaccine Market. Furthermore, the increased occurrence of cancer is fueling the growth of the Peptide Cancer Vaccine Market in this area. During the projected period, Asia Pacific is expected to be the fastest-expanding region in the Peptide Cancer Vaccine Market. This increase might be attributed to the region's growing research activity. These research endeavors improve access and promote cost-effective operational efficiency.

Key Players

The "Global Peptide Cancer Vaccine Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Boston Biomedical, VAXON Biotech, TapImmune, Sellas, ISA Pharmaceuticals, Generex Biotechnology, Immatics, OncoTherapy Science, BrightPath Biotherapeutics, Enzo Life Science, OSE Immunotherapeutics, GlaxoSmithKline PLC, Moderna Inc., Merck and Co Inc., F Hoffmann-La Roche AG, Galena Biopharma, Agenus Inc., BioNTech SE, Genexine Inc., Phosplatin Therapeutics, Provectus Biopharmaceuticals, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In December 2021, in an educational session at the ESMO Immune-Oncology Congress 2021, ISA Pharmaceuticals discussed critical learnings in cancer vaccine development.
• In November 2019, new results from a phase 1 study testing DSP-7888, an experimental WT1 cancer peptide vaccine, in patients with advanced malignancies, were presented by Boston Biomedical, Inc.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PEPTIDE CANCER VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PEPTIDE CANCER VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL PEPTIDE CANCER VACCINE MARKET, BY TECHNOLOGY

• 5.1 Overview
• 5.2 Recombinant Cancer Vaccines
• 5.3 Whole-cell Cancer Vaccines
• 5.4 Viral Vector and DNA Cancer Vaccines
• 5.5 Other Technologies (Dendritic Cells, Antigen, etc.)

6 GLOBAL PEPTIDE CANCER VACCINE MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Breast Cancer
• 6.3 Lung Cancer
• 6.4 Melanoma
• 6.5 Prostate Cancer
• 6.6 Others

7 GLOBAL PEPTIDE CANCER VACCINE MARKET, BY TYPE

• 7.1 Overview
• 7.2 Personalized Peptide Vaccine
• 7.3 Peptide-Pulsed Dendritic Cancer Vaccine
• 7.4 Peptide Cocktail Type
• 7.5 Multivalent Peptide Vaccine
• 7.6 Others

8 GLOBAL PEPTIDE CANCER VACCINE MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL PEPTIDE CANCER VACCINE MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 OSE Immunotherapeutics
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 GlaxoSmithKline PLC
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Moderna Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Merck and Co Inc.
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 F Hoffmann-La Roche AG
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 BrightPath Biotherapeutics
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Boston Biomedical
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 VAXON Biotech
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Generex Biotechnology
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 ISA Pharmaceuticals
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research